heptapeptide raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2026-01-17 and is reviewed periodically as new material appears.
Published clinical evidence is limited. Most controlled trials were conducted in Russia, enrolled modest numbers of participants, and appeared in Russian-language journals, which restricts independent verification. Reported outcomes include lower anxiety scores, improved attention and memory measures, and changes in fatigue ratings. Reviews written in English note methodological limitations such as small samples and inconsistent endpoints. Whether the compound produces clinically meaningful benefit relative to established anxiolytics is therefore an open question rather than an established finding.
Selank is a synthetic heptapeptide with the sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro. It was designed at the Institute of Molecular Genetics of the Russian Academy of Sciences as a structural analogue of tuftsin, a naturally occurring tetrapeptide fragment of the immunoglobulin heavy chain. The added Pro-Gly-Pro tail was intended to slow enzymatic degradation and extend biological activity. In Russia it is registered as an anxiolytic nasal preparation, while regulators elsewhere have not approved it for clinical use.
Identity and purity are usually assessed by reversed-phase high-performance liquid chromatography, with mass spectrometry used to confirm molecular mass and sequence information. Amino acid analysis and peptide mapping may supplement these methods. Certified reference standards are scarce, and many commercial lots are sold as research chemicals without a pharmacopoeial monograph. Regulatory treatment differs by country: Selank is a registered prescription medicine in Russia, while in the European Union and the United States it is not an approved drug and may fall under research-chemical or unapproved-product frameworks.
Selank is a hydrophilic peptide and dissolves readily in water and in aqueous buffers. The lyophilised powder is typically a white to off-white solid. Because short peptides are prone to hydrolysis and oxidation, handling benefits from limiting exposure to heat, moisture and strong light. Working solutions are commonly prepared in sterile water or saline, and repeated freeze-thaw cycles are avoided to reduce aggregation and loss of activity. These practices reflect general laboratory convention rather than published stability specifications.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C33H57N11O9 | Free peptide form |
| Molecular mass | About 751.9 Da | Calculated average mass |
| Amino acid sequence | Thr-Lys-Pro-Arg-Pro-Gly-Pro | Single-letter form TKPRPGP |
| Structural basis | Tuftsin analogue | Extended version of a natural tetrapeptide |
| Development origin | Russian Academy of Sciences | Work carried out from the 1980s onward |
Enzymatic stability motivates the extra three residues at the carboxyl end. Native tuftsin is cleaved quickly by circulating aminopeptidases and carboxypeptidases, which limits its duration of action and its usefulness as a tool compound. Extending the chain with proline-rich segments is a common design tactic because proline constrains the backbone and slows proteolysis. The same Pro-Gly-Pro motif appears in other Russian-developed peptides of the era. Whether the full seven-residue chain is required for activity, or whether it acts mainly as a prodrug releasing tuftsin, remains unresolved.
Selank is a synthetic heptapeptide with the sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro. Its four N-terminal residues reproduce tuftsin, a tetrapeptide fragment of the immunoglobulin heavy chain, while the C-terminal Pro-Gly-Pro extension is a synthetic addition. The peptide has a molecular mass near 752 daltons and carries a net positive charge at physiological pH because of the arginine and lysine side chains. Published indexes list it under the name Selank and the sequence abbreviation TKPRPGP. Solid-phase peptide synthesis is the standard production route for research quantities.
Development took place at the Institute of Molecular Genetics of the Russian Academy of Sciences, where a series of short peptides were designed in the 1980s and 1990s. Selank was selected from variants of tuftsin that showed resistance to plasma peptidases. Russian regulatory approval covers it as an anxiolytic agent given intranasally. Outside that market the compound is normally handled as a research chemical rather than a medicine, and no widely recognised international pharmacopoeial monograph exists. The name Selank is a coined trade designation rather than a systematic chemical name.
Published clinical work is concentrated in Russian-language journals and generally involves small samples without independent replication. Systematic reviews in English note the shortage of randomised, placebo-controlled trials and the difficulty of verifying methods from translated reports. Outcome measures vary between studies, which complicates pooling of results. Interest in the compound as a cognitive or anxiolytic agent therefore rests on a thinner evidence base than the volume of citations suggests. Replication in well-powered trials with preregistered endpoints would be needed before firm conclusions about efficacy can be drawn.
Proposed mechanisms centre on the GABAergic system. Animal and tissue studies report changes in GABA-A receptor expression and reduced activity of GABA transaminase, the enzyme that degrades GABA. Effects on monoamine turnover, including serotonin and dopamine pathways, are also described, and a separate line of work links the peptide to increased expression of brain-derived neurotrophic factor in hippocampal tissue. Most of these findings come from rodent models and cell preparations. How the individual observations combine into a single coherent mode of action is not settled.
Pharmacokinetic data are sparse and largely derived from animal work. After intranasal administration the peptide appears in plasma within minutes, and reported half-lives are short, on the order of minutes to tens of minutes. Degradation proceeds through ordinary proteolytic cleavage into constituent amino acids and smaller fragments. Direct evidence that intact Selank reaches brain tissue in meaningful amounts is limited, and the extent of blood-brain barrier penetration is debated. Some authors argue that fragments, not the parent peptide, carry much of the observed activity.
Most published work on selank originates from a small number of research groups in the Russian Federation. A large share of that record appears in Russian-language journals, which limits access for readers who rely on English-indexed databases. Independent replication by laboratories outside the original research network is sparse in publicly available sources. This concentration of origin and language is a frequently noted feature when the compound is summarized in broader reviews of synthetic peptides.
Reported pharmacological effects center on reduced anxiety-like behavior in animal models and on measures of memory and learning. Proposed contributing mechanisms include modulation of GABAergic signaling, shifts in monoamine turnover, and changes in the activity of enzymes that degrade neuropeptides. Effects on the expression of genes linked to neuroplasticity have also been described. No single molecular target is widely accepted, and whether the behavioral findings arise from one pathway or several remains an open question.
Selank is a synthetic heptapeptide with the sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro. It was designed as a stabilized analogue of tuftsin, a naturally occurring tetrapeptide fragment derived from the immunoglobulin heavy chain. The additional Pro-Gly-Pro segment at the carboxyl terminus is intended to slow enzymatic cleavage. The compound is usually described in the literature as a synthetic peptide with anxiolytic and cognitive-related activity, a label that reflects a research context rather than an approved therapeutic category.
Lyophilized selank is normally supplied as a dry powder and is considered stable for extended periods when kept cold and dry. Moisture uptake is the main practical threat, because absorbed water promotes both hydrolysis and aggregation in the solid state. Vials are usually warmed to room temperature before opening so that condensation does not form on the powder. Supplier documentation commonly specifies -20 °C for routine storage, with -80 °C used for material intended to be archived for years.
Once dissolved, the peptide is markedly less stable than the dry powder. Aqueous solutions are subject to backbone hydrolysis and to microbial growth when they are handled without sterile technique. Buffered solutions near neutral pH are common for short-term laboratory work, while acidic conditions are sometimes used to improve solubility. Analytical laboratories generally prepare working solutions fresh rather than storing them, and a residual water film left in a reopened vial can seed degradation even when the container appears dry.
Working at the Royal Society in the 1660s, the physician Richard Lower began examining the effects of changes in blood volume on circulatory function and developed methods for cross-circulatory study in animals, obviating clotting by closed arteriovenous connections. The new instruments he was able to devise enabled him to perform the first reliably documented successful transfusion of blood in front of his distinguished colleagues from the Royal Society. According to Lower's account, "...towards the end of February 1665 [I] selected one dog of medium size, opened its jugular vein, and drew off blood, until its strength was nearly gone. Then, to make up for the great loss of this dog by the blood of a second, I introduced blood from the cervical artery of a fairly large mastiff, which had been fastened alongside the first, until this latter animal showed ... it was overfilled ... by the inflowing blood." After he "sewed up the jugular veins", the animal recovered "with no sign of discomfort or of displeasure". Lower had performed the first blood transfusion between animals. He was then "requested by the Honorable [Robert] Boyle ... to acquaint the Royal Society with the procedure for the whole experiment", which he did in December 1665 in the Society's Philosophical Transactions. The first blood transfusion from animal to human was administered by Jean-Baptiste Denys, eminent physician to King Louis XIV of France, on June 15, 1667. He transfused the blood of a sheep into a 15-year-old boy, who survived the transfusion.
callus An unorganized mass of parenchymal cells that forms naturally at the site of wounds in plant tissues, and which is commonly artificially induced to form in plant tissue culture as a means of initiating somatic embryogenesis.
I was amazed to see today in the Vorwärts an excerpt from my 'Introduction' that had been printed without my knowledge and tricked out in such a way as to present me as a peace-loving proponent of legality [at all costs]. Which is all the more reason why I should like it to appear in its entirety in the Neue Zeit in order that this disgraceful impression may be erased. I shall leave Liebknecht in no doubt as to what I think about it and the same applies to those who, irrespective of who they may be, gave him this opportunity of perverting my views and, what's more, without so much as a word to me about it.
Medical availability and clinical practice vary across the world due to regional differences in culture and technology. Modern scientific medicine is highly developed and widespread in the Western world, whereas in some low-resource regions—including parts of Africa, the Pacific Islands of Oceania, Southeast Asia, and Latin America—populations often rely more heavily on traditional medicine. These practices consist of decentralized training structures and vary widely in empirical support; consequently, they may lack formal regulatory oversight or robust evidence for clinical efficacy. In the developed world, evidence-based medicine (EBM) is not universally applied in clinical practice; for example, a 2007 survey of literature reviews found that about 49% of medical interventions lacked sufficient evidence to support either benefit or harm. However, medical practitioners who apply an intervention with uncertain efficacy without adequate justification, transparency, or patient consent may violate the bioethical principle of non-maleficence, a core tenet of biomedical ethics historically associated with the Hippocratic Oath, which emphasizes a primary duty to "first, do no harm." In modern clinical practice, physicians and mid-level practitioners such as physician assistants personally assess patients to diagnose, prognose, treat, and prevent disease using clinical judgment. An initial medical encounter with a patient typically begins with a review of the patient's medical history and medical record, followed by a medical interview and a physical examination.
== Contraindications == Octreotide has not been adequately studied for the treatment of children as well as pregnant and lactating women. The medication is given to these groups only if a risk-benefit analysis is positive.
Sources: en.wikipedia.org
=== Pharmacokinetics === Metribolone has very low affinity for human serum sex hormone-binding globulin (SHBG), less than 5% of that of testosterone and less than 1% of that of dihydrotestosterone (DHT).
== Experimental atomic gas phase chemistry == Interest in copernicium's chemistry was sparked by predictions that it would have the largest relativistic effects in the whole of period 7 and group 12, and indeed among all 118 known elements. Copernicium is expected to have the ground state electron configuration [Rn] 5f14 6d10 7s2 and thus should belong to group 12 of the periodic table, according to the Aufbau principle. As such, it should behave as the heavier homologue of mercury and form strong binary compounds with noble metals like gold. Experiments probing the reactivity of copernicium have focused on the adsorption of atoms of element 112 onto a gold surface held at varying temperatures, in order to calculate an adsorption enthalpy. Owing to relativistic stabilization of the 7s electrons, copernicium shows radon-like properties. Experiments were performed with the simultaneous formation of mercury and radon radioisotopes, allowing a comparison of adsorption characteristics. The first chemical experiments on copernicium were conducted using the 238U(48Ca,3n)283Cn reaction. Detection was by spontaneous fission of the claimed parent isotope with half-life of 5 minutes. Analysis of the data indicated that copernicium was more volatile than mercury and had noble gas properties. However, the confusion regarding the synthesis of copernicium-283 has cast some doubt on these experimental results.
=== IgE-independent activation === The most versatile IgE-independent receptor is known as MrgprB2 in mice and MRGPRX2 in humans. These receptors can recognize many different, mostly positively charged compounds. MrgprB2 is expressed in connective tissue mast cells but not in mucosal mast cells of mice. Binding of ligands to MrgprB2 results in activation of G-protein-signaling pathways.
In 1872, Russian Alexander Lodygin invented an incandescent light bulb and obtained a Russian patent in 1874. He used as a burner two carbon rods of diminished section in a glass receiver, hermetically sealed, and filled with nitrogen, electrically arranged so that the current could be passed to the second carbon when the first had been consumed. Later he lived in the US, changed his name to Alexander de Lodyguine and applied for and obtained patents for incandescent lamps having chromium, iridium, rhodium, ruthenium, osmium, molybdenum and tungsten filaments. On 24 July 1874, a Canadian patent was filed by Henry Woodward and Mathew Evans for a lamp consisting of carbon rods mounted in a nitrogen-filled glass cylinder. They were unsuccessful at commercializing their lamp, and sold rights to their patent to Thomas Edison in 1879. (Edison needed ownership of the novel claim of lamps connected in a parallel circuit.) The government of Canada maintains that it is Woodward and Evans who invented the lightbulb.
The DNA in an organism's genome can be analyzed to diagnose vulnerabilities to inherited diseases, and can also be used to determine a child's paternity (genetic father) or a person's ancestry. Normally, every person carries two variations of every gene, one inherited from their mother, the other inherited from their father. The human genome is believed to contain around 20,000–25,000 genes. In addition to studying chromosomes to the level of individual genes, genetic testing in a broader sense includes biochemical tests for the possible presence of genetic diseases, or mutant forms of genes associated with increased risk of developing genetic disorders. Genetic testing identifies changes in chromosomes, genes, or proteins. Usually, testing is used to find changes that are associated with inherited disorders. The results of a genetic test can confirm or rule out a suspected genetic condition or help determine a person's chance of developing or passing on a genetic disorder. Several hundred genetic tests are currently in use, and more are being developed.
Sources: en.wikipedia.org
North America For the United States, the GLC, advertised as the Great Little Car, was only offered with one engine at a time. The new GLC overlapped with the old-style Mizer for part of 1977 and was produced through 1980 before being replaced by the next-generation GLC. The marketing campaign in the U.S. had the words "Great Little Car" set to the tune of Spanish Flea. Thanks to the safety bumpers mandated by federal regulations, the 1979 base GLC three-door weighed in at 1,995 lb (905 kg) and was 154.3 in (3,920 mm) long. The station wagon continued to be offered until the 1986 model year. For the 1979 model year, the original 52 hp (39 kW) 1272 cc four was replaced with a 1415 cc engine producing 65 hp (48 kW). In addition to three- and five-door hatchbacks, as well as the wagon, there was also a GLC Sport version which offered a five-speed rather than the four-speed manual or the three-speed automatic installed in other versions. After the introduction of the front-wheel-drive GLC the carry-over station wagon's engine was replaced with the new E5 model of 1490 cc, although claimed power dropped somewhat, to 63 hp (47 kW).
Reith revealed in a 2009 letter to the Journal of the Royal College of Physicians of Edinburgh that she and her colleagues made no money from the invention, with the then Greater Glasgow Health Board holding the patent on their behalf and receiving income until it sold the rights to pharmaceutical company Novo.
where γ is the gyromagnetic ratio. Classically, this corresponds to the proportionality between the angular momentum and the magnetic dipole moment of a spinning charged sphere, both of which are vectors parallel to the rotation axis whose length increases proportional to the spinning frequency. It is the magnetic moment and its interaction with magnetic fields that allows the observation of NMR signal associated with transitions between nuclear spin levels during resonant RF irradiation or caused by Larmor precession of the average magnetic moment after resonant irradiation. Nuclides with even numbers of both protons and neutrons have zero nuclear magnetic dipole moment and hence do not exhibit NMR signal. For instance, 18O is an example of a nuclide that produces no NMR signal, whereas 13C, 31P, 35Cl and 37Cl are nuclides that do exhibit NMR spectra. The last two nuclei have spin S > 1/2 and are therefore quadrupolar nuclei. Electron spin resonance (ESR) is a related technique in which transitions between electronic rather than nuclear spin levels are detected. The basic principles are similar but the instrumentation, data analysis, and detailed theory are significantly different. Moreover, there is a much smaller number of molecules and materials with unpaired electron spins that exhibit ESR (or electron paramagnetic resonance (EPR)) absorption than those that have NMR absorption spectra. On the other hand, ESR has much higher signal per spin than NMR does.
in the bond orders within the rings, in the number of methyl groups attached to the ring (and, when present, on the prominent side chain at C17), in the functional groups attached to the rings and side chain, and in the configuration of groups attached to the rings and chain. For instance, sterols such as cholesterol and lanosterol have a hydroxyl group attached at position C-3, while testosterone and progesterone have a carbonyl (oxo substituent) at C-3. Among these compounds, only lanosterol has two methyl groups at C-4. Cholesterol which has a C-5 to C-6 double bond, differs from testosterone and progesterone which have a C-4 to C-5 double bond.
== Difference between xeno-, exo-, and astro-biology == "Astro" means "star" and "exo" means "outside". Both exo- and astrobiology deal with the search for naturally evolved life in the Universe, mostly on other planets in the circumstellar habitable zone. (These are also occasionally referred to as xenobiology.) Whereas astrobiologists are concerned with the detection and analysis of life elsewhere in the Universe, xenobiology attempts to design forms of life with a different biochemistry or different genetic code than on planet Earth.
Sources: en.wikipedia.org
It is a seven-amino-acid peptide, Thr-Lys-Pro-Arg-Pro-Gly-Pro, produced by chemical synthesis rather than extracted from biological tissue. Its design is based on tuftsin, a natural immunomodulatory tetrapeptide. The C-terminal Pro-Gly-Pro segment is a common stabilising motif in short regulatory peptides.
The core four residues correspond to tuftsin, which occurs naturally as part of immunoglobulin G. The full seven-residue sequence, however, is not a known endogenous peptide. It is a laboratory-designed analogue intended to combine tuftsin-like activity with greater resistance to breakdown.
No single receptor has been confirmed as the primary target. Reports describe involvement of the GABAergic system, interference with enkephalin degradation, and shifts in neurotrophic factor expression. Because these observations come from different models and assays, they have not yet been integrated into one accepted mechanism.
Dry powder is normally held at -20 degrees Celsius or below in a sealed, light-protected container with desiccant. Brief room-temperature handling during weighing is generally tolerated. Storage instructions vary between suppliers, so the accompanying certificate of analysis should be followed.